Selective MC4R Peptide Composition to Limit MC1R Hyperpigmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing MC4R agonists for treating obesity-related disorders cause undesirable side effects such as hyperpigmentation due to cross-activation of other melanocortin receptors like MC1R, necessitating the development of compositions and methods that enhance MC4R selectivity while minimizing these side effects.
Innovation Solution
Development of peptides with specific amino acid sequences, including cyclic peptides with disulfide or lactam bridges, that demonstrate increased selectivity for MC4R over MC1R, reducing hyperpigmentation and enhancing MC4R function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pan-melanocortin receptor activating peptides are administered to treat MC4R-related diseases, then MC4R signaling activity is improved, but cross-activation of other melanocortin receptors causes undesirable side effects such as hyperpigmentation
Solution Approach 1:
The patent applies local quality by designing peptides with specific amino acid modifications at particular positions (e.g., X3 as Aib(O-cyclic), X4 as Gln/hCit/Cit/3-Pal/hGln/His/Orn) to achieve selective activation of MC4R while avoiding cross-activation of other melanocortin receptors like MC1R. This localized structural optimization enables the peptide to interact preferentially with MC4R binding sites, thereby improving MC4R signaling reliability while minimizing harmful hyperpigmentation side effects caused by off-target receptor activation.
Solution Approach 2:
The patent employs parameter changes by systematically varying amino acid sequences and structural parameters of the peptides (including cyclic vs. linear configurations, different amino acid residues at specific positions, and disulfide bridge formations) to optimize selectivity for MC4R. These parameter modifications alter the peptide's binding affinity and specificity, enabling enhanced MC4R activation while reducing cross-reactivity with other melanocortin receptors, thus resolving the contradiction between therapeutic efficacy and side effect minimization.
2Productivity
If MC4R agonists are administered to treat obesity, then weight loss is achieved, but hyperpigmentation side effects occur due to cross-activation of MC1R
Solution Approach 1:
The patent applies local quality by introducing specific amino acid modifications at key positions within the peptide sequence (e.g., X3 as Aib(O-cyclic), X4 as various amino acids including Gln, hCit, Cit, 3-Pal, hGln, His, or Orn) to create localized interaction differences with MC4R versus MC1R. These localized structural features enable the peptide to maintain high binding affinity for MC4R (achieving weight loss efficacy) while reducing affinity for MC1R (minimizing hyperpigmentation), thereby resolving the contradiction between therapeutic productivity and harmful side effects.
Solution Approach 2:
The patent employs parameter changes by systematically modifying peptide structural parameters including amino acid composition, cyclic vs. linear configuration, disulfide bridge placement, and N-terminal/C-terminal modifications. These parameter variations optimize the peptide's pharmacological profile to enhance MC4R-mediated weight loss while reducing off-target MC1R activation that causes hyperpigmentation, thus resolving the contradiction between treatment efficacy and side effect reduction.
3Object-generated harmful factors
If peptides with high MC4R selectivity are designed, then hyperpigmentation is reduced, but peptide structural complexity increases
Solution Approach 1:
The patent applies local quality by implementing targeted amino acid modifications at specific positions (X3 as Aib(O-cyclic), X4 as selected amino acids) rather than throughout the entire peptide sequence. This localized approach achieves high MC4R selectivity and hyperpigmentation reduction while limiting structural complexity increases to only the necessary residues, maintaining relative simplicity in non-critical regions of the peptide structure.
Solution Approach 2:
The patent employs parameter changes by systematically optimizing specific structural parameters (amino acid identity at key positions, cyclic configuration, disulfide bridge formation) to achieve the desired balance between selectivity and complexity. By focusing parameter modifications on critical binding regions rather than the entire peptide, the invention reduces hyperpigmentation through enhanced MC4R selectivity while controlling overall structural complexity to practical levels.
Data Source
AI summary
The present disclosure relates to, inter alia, MC4R agonists and enhanced selectivity of MC4R over MC1R. Furthermore, the present disclosure relates to methods of treating metabolic disorders or diseases.